ReviewPlant biotechnology journal2020
Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective.
Review in Plant biotechnology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed.
- Molecular mechanisms and agronomic strategies for thermotolerance in chili pepper (Capsicum annuum L.).Plant cell reports · 2026Review
- Genome Editing Approaches in Flax (International journal of molecular sciences · 2026Review
- AI-Guided DNA-Free and Genotype-Independent Genome Editing for Soybean Improvement.Plants (Basel, Switzerland) · 2026Review
- Functions and optimization of soft law in the international governance of synthetic biology: The predicament of hard law vs. the rise of soft law.Synthetic and systems biotechnology · 2026Article
- Non-viral delivery of genome-editing tools for treatment of genetic disorders.Acta pharmaceutica Sinica. B · 2026Review
- The emerging impact of CRISPR and gene editing on global crop improvement.Transgenic research · 2026Review
- A 90-day safety study of meat from MSTN gene-edited Mongolian cattle in mice.Scientific reports · 2026Article
- Next-generation CRISPR systems and advanced delivery paradigms for precision crop improvement: a comparative case study in sugar beet (Frontiers in plant science · 2026Review
- Rethinking gene-edited crop regulation: advancing a Principle-based framework for modern biotechnology governance.GM crops & food · 2025Review
- CRISPR/Cas9 a genomic engineering technology for treatment in ALS mouse models.Regenerative therapy · 2025Review
- Exploring CRISPR/Cas9-Mediated Gene Editing Advances in Conventional and Non-conventional Yeast Species.Applied biochemistry and biotechnology · 2025Review
- The Enhancement of Fungal Disease Resistance in Major Staple Crops Using CRISPR-Cas Technology.Genes · 2025Review
- Efficient creation of decorative double-flowered petunia through CRISPR/Cas9-mediated simultaneous editing of PMADS3 and FBP6 genes.Plant biotechnology journal · 2025Article
- Application progress and biosafety challenges of gene editing and synthetic biotechnology in diagnosis, treatment and prevention of infectious diseases.Biosafety and health · 2025Review
- CRISPR-Cas Gene Editing Technology in Potato.International journal of molecular sciences · 2025Review
- Genome-wide identification and functional analysis of PEL gene family in Brassica napus L.BMC plant biology · 2025Article
- Heat stress-induced sterility in oilseed crops: a focus on Brassica napus.Molecular biology reports · 2025Review
- Strategies to develop climate-resilient chili peppers: transcription factor optimization through genome editing.Planta · 2025Review
- Genome editing in maize and sorghum: A comprehensive review of CRISPR/Cas9 and emerging technologies.The plant genome · 2025Review
- Biosafety considerations triggered by genome-editing technologies.Biosafety and health · 2025Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last three decades, the development of new genome editing techniques, such as ODM, TALENs, ZFNs and the CRISPR-Cas system, has led to significant progress in the field of plant and animal breeding. The CRISPR-Cas system is the most versatile genome editing tool discovered in the history of molecular biology because it can be used to alter diverse genomes (e.g. genomes from both plants and animals) including human genomes with unprecedented ease, accuracy and high efficiency. The recent development and scope of CRISPR-Cas system have raised new regulatory challenges around the world due to moral, ethical, safety and technical concerns associated with its applications in pre-clinical and clinical research, biomedicine and agriculture. Here, we review the art, applications and potential risks of CRISPR-Cas system in genome editing. We also highlight the patent and ethical issues of this technology along with regulatory frameworks established by various nations to regulate CRISPR-Cas-modified organisms/products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.